Related Experiment Videos
Osteosarcomas and other cancers of bone
1Medical Oncology, London Regional Cancer Centre, Ontario, Canada. vivien.bramwell@lrcc.on.ca
Abstract:
The results of several studies suggest that alterations in various cell cycle regulatory genes are involved in the pathogenesis of osteosarcomas. Experiments in animal models provide preliminary data on the feasibility of gene therapy in osteosarcoma and chondrosarcoma. Prediction of response to chemotherapy remains a major focus of imaging research. Several clinicopathologic studies have explored the mechanisms underlying multidrug resistance in osteosarcoma patients receiving neoadjuvant chemotherapy. HER2/erbB2 expression, linked to poor prognosis, has been proposed as a therapeutic target in osteosarcoma. In clinical studies of osteosarcoma, further data confirm the activity of ifosfamide and carboplatin but provide little support for the use of immunotherapy. A retrospective analysis showed no value for dose intensification of doxorubicin/cisplatin, but the results of a prospective trial should be more informative. Recent evidence confirms that secondary osteosarcomas and malignant fibrous histiocytomas of bone should be treated with aggressive chemotherapy regimens, similar to those used for osteosarcomas.
Insights
Research into osteosarcoma reveals cell cycle gene alterations in pathogenesis. Gene therapy shows promise, while chemotherapy response prediction and multidrug resistance mechanisms are key research areas.
Area of Science:
- Oncology
- Genetics
- Biomedical Research
Background:
- Osteosarcoma pathogenesis involves alterations in cell cycle regulatory genes.
- Gene therapy presents preliminary feasibility for osteosarcoma and chondrosarcoma.
- Predicting chemotherapy response is a critical area in osteosarcoma imaging research.
Purpose of the Study:
- To review current research on osteosarcoma pathogenesis, treatment strategies, and therapeutic targets.
- To explore the role of gene therapy, chemotherapy response prediction, and multidrug resistance.
- To evaluate the efficacy of various chemotherapeutic agents and potential new targets like HER2/erbB2.
Main Methods:
- Review of existing clinicopathologic and experimental studies on osteosarcoma.
- Analysis of data regarding gene therapy feasibility in animal models.
- Examination of research on chemotherapy response prediction and multidrug resistance mechanisms.
Main Results:
- Cell cycle gene alterations are implicated in osteosarcoma development.
- Ifosfamide and carboplatin show confirmed activity; immunotherapy has limited support.
- HER2/erbB2 expression is linked to poor prognosis and is a potential therapeutic target.
Conclusions:
- Osteosarcoma treatment research focuses on genetic alterations, gene therapy, and chemotherapy optimization.
- Understanding multidrug resistance and identifying therapeutic targets like HER2/erbB2 are crucial.
- Aggressive chemotherapy regimens are recommended for secondary osteosarcomas and malignant fibrous histiocytomas of bone.